Saturday, 31 October 2026European Markets

TECHSTEP Stock Went Up By Over 22% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of TECHSTEP (Oslo Børs Benchmark Index_GI: TECH.OL) rose by a staggering 22.01% in 10 sessions from kr1.29 to kr1.58 at 17:39 EST on Tuesday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is dropping 0.89% to kr1,202.34, after two successive sessions in a row of gains.

TECHSTEP's last close was kr1.60, 50% below its 52-week high of kr3.19.

About TECHSTEP

Techstep ASA operates as a mobile technology enabler in Norway, Sweden, Denmark, and Poland. It offers mobile hardware, service, support, and mobility consultancy services; software as a service, as well as mobile expense management modules; and financing and remarketing services. The company also provides industry-leading cloud-based PBX solutions and enterprise mobility management services, including mobile security, system design, implementation, and mobile device management. In addition, it develops and provides enterprise mobility software and solutions for the customers in the transportation, logistics, and public safety sectors, as well as offers mobile device lifecycle management solutions. The company was founded in 2016 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, TECHSTEP has a trailing twelve months EPS of kr-0.34.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -12.18%.

Volume

Today's last reported volume for TECHSTEP is 16756 which is 97.66% below its average volume of 339548.

More news about TECHSTEP (TECH.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com